Ajanta Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹5,453cr+17.3% on FY25
EBITDA: ₹1,395cr+10.7% on FY25
Net profit: ₹1,056cr+14.7% on FY25
EPS: ₹84.53+14.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	5,776	5,453	4,648	4,209	3,743	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	217	172	94.5	84.6	98.6
	5,993	5,625	4,743	4,293	3,841
	1,006	917	847	939	878
	245	230	250	166	146
	−15.3	37.5	−25.6	−39.2	25.8
	1,369	1,291	1,090	900	785
	14.0	16.1	20.7	7.2	5.8
	176	173	144	135	131
	1,704	1,583	1,228	1,070	1,124
	4,499	4,247	3,553	3,179	3,096
	1,467	1,395	1,260	1,172	783
	1,291	1,222	1,115	1,037	652
Profit
	1,493	1,378	1,189	1,114	745
	1,493	1,378	1,189	1,114	745
	329	300	312	322	197
	29.1	21.6	−43.5	−24.3	−40.0
	358	322	269	298	157
	1,135	1,056	920	816	588
	1,135	1,056	920	816	588
	24.7	29.1	1.9	0.8	14.9
	1,160	1,085	922	817	603
	1,131	1,056	920	817	588
Per share
	₹90.84	₹84.53	₹73.56	₹64.82	₹45.89
	₹90.79	₹84.51	₹73.53	₹64.77	₹45.89
Other comprehensive income — detail
	24.7	29.1	1.9	—	—
	−0.6	−0.5	−9.0	−3.9	−3.5
	−0.2	−0.2	−3.1	−1.4	−1.2
	—	—	—	−1.4	−1.2
	25.0	29.4	7.7	3.3	17.1
	1,160	1,085	922	818	—
Per share — as-filed variants
	₹90.84	₹84.53	₹73.56	₹64.82	₹45.89
	₹90.79	₹84.51	₹73.53	₹64.77	₹45.89
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	4,540	4,269	3,577	3,142	2,692
	78.6%	78.3%	77.0%	74.7%	71.9%
Adjusted (ex-exceptional items) — derived
	1,493	1,378	1,189	1,114	745
	1,135	1,056	920	816	588
	₹90.84	₹84.53	₹73.56	₹64.82	₹45.89

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AJANTPHARM₹3,459.80

Ajanta Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹43,369 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	3,742.6	4,208.7	4,648.1	5,452.9	5,776.2
Other Income	98.6	84.6	94.5	172.1	216.6
Total Income	3,841.3	4,293.3	4,742.6	5,624.9	5,992.8
Expenses
+ Cost of Materials Consumed	878.4	939.4	846.6	916.5	1,005.9
+ Purchases of Stock-in-Trade	146.3	166.4	249.8	229.8	245.1
+ Changes in Inventories	25.8	-39.2	-25.6	37.5	-15.3
+ Employee Benefit Expense	785.1	900.3	1,089.7	1,291.2	1,369.4
+ Finance Costs	5.8	7.2	20.7	16.1	14.0
+ Depreciation & Amortisation	130.8	135.4	144.1	173.1	176.4
+ Other Expenses	1,123.9	1,069.9	1,228.2	1,583.1	1,704.0
Total Expenses	3,096.0	3,179.4	3,553.4	4,247.3	4,499.5
EBITDA	783.3	1,171.9	1,259.5	1,394.8	1,467.1
EBIT	652.5	1,036.5	1,115.4	1,221.7	1,290.7
Profit
PBT before Exceptional Items	745.3	1,113.9	1,189.2	1,377.7	1,493.3
Pretax Income	745.3	1,113.9	1,189.2	1,377.7	1,493.3
+ Current Tax	197.2	322.1	312.3	300.1	329.3
+ Deferred Tax	-40.0	-24.3	-43.5	21.6	29.1
Tax Expense	157.3	297.8	268.8	321.7	358.4
Net Income	588.0	816.2	920.4	1,056.0	1,134.9
+ Net Income — Continuing Ops	588.0	816.2	920.4	1,056.0	1,134.9
+ Other Comprehensive Income	14.9	0.8	1.9	29.1	24.7
Total Comprehensive Income	602.8	817.0	922.2	1,085.1	1,159.5
Net Income to Common	588.0	817.0	920.4	1,056.0	1,130.6
Per Share
Basic EPS	45.89	64.82	73.56	84.53	90.84
Diluted EPS	45.89	64.77	73.53	84.51	90.79
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	1.9	29.1	24.7
+ Items NOT to be Reclassified to P&L	-3.5	-3.9	-9.0	-0.5	-0.6
+ Tax on Items NOT to be Reclassified	-1.2	-1.4	-3.1	-0.2	-0.2
+ Tax on Items NOT to be Reclassified — alt tag	-1.2	-1.4	—	—	—
+ Items to be Reclassified to P&L	17.1	3.3	7.7	29.4	25.0
Comprehensive Income — Owners of Parent	—	817.8	922.2	1,085.1	1,159.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	45.89	64.82	73.56	84.53	90.84
Diluted EPS — Continuing Operations	45.89	64.77	73.53	84.51	90.79
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,692.2	3,142.1	3,577.3	4,269.1	4,540.4
Gross Margin %	71.93	74.66	76.96	78.29	78.61
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	745.3	1,113.9	1,189.2	1,377.7	1,493.3
Net Income Adj (tax-effected)	588.0	816.2	920.4	1,056.0	1,134.9
EPS Adj	45.89	64.82	73.56	84.53	90.84
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	25.3	25.3	25.1	25.1	25.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.